21-Dehydro Budesonide-d8-1

21-Dehydro Budesonide-d8-1

• UNSPSC Description: 21-Dehydro Budesonide-d8-1 is deuterated labeled dehydrogenated Budesonide (HY-13580). Budesonide is an orally available glucocorticoid receptor agonist with anti-cancer activity. 21-Dehydro Budesonide-d8-1 acts as a probe for glucocorticoid receptors and is used in isotope tracing studies[1].
• Target Antigen: Glucocorticoid Receptor; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Immunology/Inflammation;Others;Vitamin D Related/Nuclear Receptor
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Solubility: 10 mM in DMSO
• Smiles: O=CC([C@]12[C@]3(C)[C@@]([H])(C[C@]1(OC([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])O2)[H])[C@]4([C@]([H])([C@@H](O)C3)[C@]5(C)C(CC4)=CC(C=C5)=O)[H])=O
• Molecular Weight: 436.57
• References & Citations: [1]Claudia Grossmann, et al. Transactivation via the Human Glucocorticoid and Mineralocorticoid Receptor by Therapeutically Used Steroids in CV-1 Cells: A Comparison of Their Glucocorticoid and Mineralocorticoid Properties. Eur J Endocrinol. 2004 Sep;151(3):.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported